Search

Your search keyword '"Mepolizumab, severe asthma, EGPA"' showing total 1 results
Start Over Descriptor "Mepolizumab, severe asthma, EGPA"
1 results on '"Mepolizumab, severe asthma, EGPA"'

1. Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase

Author

Giovanni Orsolini, Alessandro Giollo, Matteo Maule, Ernesto Crisafulli, Giuliana Festi, Marco Caminati, Claudio Lunardi, Gianenrico Senna, and Claudio Micheletto

Subjects
severe asthma, medicine.medical_specialty, Antibodies, Monoclonal, Humanized, Eosinophils, Humans, Anti-Asthmatic Agents, Churg-Strauss Syndrome, Churg-strauss syndrome, Gastroenterology, Anti-asthmatic Agent, Antibodies, Internal medicine, Monoclonal, Remission phase, medicine, Immunology and Allergy, Asthmatic patient, Humanized, Mepolizumab, Mepolizumab, severe asthma, EGPA, business.industry, Mepolizumab 100 MG, medicine.disease, EGPA, business
Published
2020

Catalog

Books, media, physical & digital resources
See catalog results